Investment analysts at Jefferies Financial Group assumed coverage on shares of Kyowa Kirin (OTCMKTS:KYKOF) in a research note issued to investors on Monday, The Fly reports. The firm set a “buy” rating on the stock.

OTCMKTS KYKOF opened at $21.65 on Monday.

Kyowa Kirin Company Profile

Kyowa Kirin Co, Ltd., specialty pharmaceutical company, manufactures and markets pharmaceuticals focused on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide. Its products include ABSTRAL, a sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; GRAN, a human colony-stimulating factor; and G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia.

Read More: Limitations to arbitrage trading

The Fly

Receive News & Ratings for Kyowa Kirin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kyowa Kirin and related companies with's FREE daily email newsletter.